Diakonie in Suedwestfalen gGmbH
- Address
- lock Available on a paid plan
Neoplasms and Breast Cancer Research
At Diakonie in Suedwestfalen gGmbH in Siegen, clinical research in oncology focuses on HR+/HER2- early breast cancer and hormone receptor positive breast cancer. These studies are designed to refine treatment choices, compare modern targeted approaches with standard care, and improve long-term outcomes for patients.
- Evaluating whether endocrine therapy combined with ribociclib can improve disease control in early breast cancer
- Assessing treatment effectiveness for hormone receptor-positive, HER2-negative advanced breast cancer
- Supporting more personalized cancer care by comparing new therapy options with established treatment strategies
This area of research aims to strengthen breast cancer care through better survival outcomes and more tailored treatment selection.
Hemic and Lymphatic Diseases in Central Nervous System Lymphoma
The site is also involved in research on primary diffuse large B-cell lymphoma of the central nervous system, a rare and serious form of lymphoma. The trial work here is centered on improving treatment effectiveness for older patients and finding approaches that may extend survival while maintaining quality of life.
- Comparing intensified chemotherapy followed by autologous stem-cell transplantation with conventional treatment
- Studying progression-free survival and other outcomes in elderly patients with newly diagnosed disease
- Exploring whether a more intensive treatment strategy can offer better control of this difficult-to-treat lymphoma
This research reflects an important effort in hematology and neuro-oncology to improve care for patients with limited treatment options.
Targeted Therapy for Advanced Breast Cancer
Another key area of investigation at this hospital is the study of patritumab deruxtecan for hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer. The goal is to determine whether this new therapy can improve outcomes compared with current physician-selected treatment options.
- Testing a novel HER3-targeted treatment for advanced breast cancer
- Comparing progression-free survival and overall survival against standard treatment choices
- Advancing options for patients whose cancer has spread or cannot be removed surgically
This work highlights the site’s role in evaluating innovative cancer therapies that may offer more effective control of advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1BeOne Medicines AG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diakonie in Suedwestfalen gGmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1) | University Of Saarland | Phase III | Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 2 | Unknown | 2023-04-24 | 2023-08-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.